Researchers discovered that mechanotherapy on damaged muscle tissue reduces both fibrotic tissue accumulation and inflammation while helping to increase tissue regeneration, according to a new study titled “Biologic-free mechanically induced muscle regeneration,” published in the journal Proceedings of the National Academy of Sciences (PNAS). Although focusing on the repair…
https://www.youtube.com/watch?v=98vpzgy94kk Learn more about IPF: http://bit.ly/1QiRmr3…
Watch the president and CEO of the Pulmonary Fibrosis Foundation, Dr. Daniel M. Rose, talk about the disease. Learn more about IPF: http://bit.ly/1QiRmr3…
Spherix Global Insights, GmbH, a business intelligence and market research company based in Switzerland, recently reported a study revealing that idiopathic pulmonary fibrosis (IPF) remains a challenge in terms of treatment, especially since the majority of patients are diagnosed at already advanced disease stages. The Spherix…
UT Health Northeast, a medical center that is part of the University of Texas system, recently announced in a press release that four of its scientists have received a total of $2.1 million in competitive research grants. The researchers are Dr. Vijay Rao, Dr. Krishna Vankayalapati, Dr. Hong-Long Ji,…
“Ever wanted to know what NOT to say to someone living with a chronic illness? Well here is your 101 on things you probably shouldn’t say.” Learn more about pulmonary fibrosis: http://bit.ly/1lfMsiZ…
Learn more about IPF: http://bit.ly/1QiRmr3…
Last week’s hot topic on pulmonary fibrosis was NY Times Covers Story of IPF Patient’s Progress with Esbriet Treatment written by Isaura Santos. This article follows a story covered by the NY Times, about an IPF patient’s…
A European survey of patients with idiopathic pulmonary fibrosis (IPF) found that patients well understand the disease’s significant physical and emotional impact on their quality of life, and are frustrated by a perceived lack of quality IPF information and public understanding. The study also underscored the beneficial role of patients’ caregivers and specialist nurses, where available.
A new article that reviews available treatment options for idiopathic pulmonary fibrosis (IPF) took a critical but positive look at available research information for OFEV (nintedanib). The article focuses on the clinical evidence supporting nintedanib as an IPF treatment and on the drug’s pharmacological characteristics. The article, titled “Idiopathic…
Get regular updates to your inbox.
